Selected research
Market Structure
Global Non-Insulin Hypoglycemic Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Non-Insulin Hypoglycemic Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Non-Insulin Hypoglycemic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Non-Insulin Hypoglycemic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Non-Insulin Hypoglycemic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Non-Insulin Hypoglycemic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Non-Insulin Hypoglycemic Drug include GSK, Takeda, Merck, Uni-Bio Science Group, Eli Lilly, Jiangsu Hengrui Medicine, Jiangsu Hansoh Pharmaceutical, Pfizer and Sumitomo Dainippon Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Non-Insulin Hypoglycemic Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Non-Insulin Hypoglycemic Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Non-Insulin Hypoglycemic Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Non-Insulin Hypoglycemic Drug market size, projected growth trends, production technologies, key applications, and end-use industries.
Non-Insulin Hypoglycemic Drug Segment by Company
GSK
Takeda
Merck
Uni-Bio Science Group
Eli Lilly
Jiangsu Hengrui Medicine
Jiangsu Hansoh Pharmaceutical
Pfizer
Sumitomo Dainippon Pharma
Servier
Novo Nordisk
Luye Pharma Group
Intarcia Therapeutics
Geropharm
Eurofarma
Emisphere
Dong-A Pharmaceutical
Alkem Labs
3SBio
Non-Insulin Hypoglycemic Drug Segment by Type
Alpha Glucosidase Inhibitors
Meglitinides
Sulfonylureas
Thiazolidinediones
Biguanides
Others
Non-Insulin Hypoglycemic Drug Segment by Application
Hospital Pharmacies
Retail Pharmacies
Non-Insulin Hypoglycemic Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Non-Insulin Hypoglycemic Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Non-Insulin Hypoglycemic Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Non-Insulin Hypoglycemic Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Non-Insulin Hypoglycemic Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-Insulin Hypoglycemic Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Non-Insulin Hypoglycemic Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Non-Insulin Hypoglycemic Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
List of Tables
Table 1. Non-Insulin Hypoglycemic Drug Industry Trends
Table 2. Non-Insulin Hypoglycemic Drug Industry Drivers
Table 3. Non-Insulin Hypoglycemic Drug Industry Opportunities and Challenges
Table 4. Non-Insulin Hypoglycemic Drug Industry Restraints
Table 5. Global Non-Insulin Hypoglycemic Drug Revenue by Manufacturers (US$ Million) & (2021-2026)
Table 6. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Manufacturers (2021-2026)
Table 7. Global Non-Insulin Hypoglycemic Drug Sales by Manufacturers (K Units) & (2021-2026)
Table 8. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Manufacturers
Table 9. Global Non-Insulin Hypoglycemic Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026)
Table 10. Global Non-Insulin Hypoglycemic Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
Table 11. Global Non-Insulin Hypoglycemic Drug Key Manufacturers Manufacturing Sites & Headquarters
Table 12. Global Non-Insulin Hypoglycemic Drug Manufacturers, Product Type & Application
Table 13. Global Non-Insulin Hypoglycemic Drug Manufacturers Establishment Date
Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Global Non-Insulin Hypoglycemic Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025)
Table 16. Major Manufacturers of Alpha Glucosidase Inhibitors
Table 17. Major Manufacturers of Meglitinides
Table 18. Major Manufacturers of Sulfonylureas
Table 19. Major Manufacturers of Thiazolidinediones
Table 20. Major Manufacturers of Biguanides
Table 21. Major Manufacturers of Others
Table 22. Global Non-Insulin Hypoglycemic Drug Sales by Type 2021 VS 2025 VS 2032 (K Units)
Table 23. Global Non-Insulin Hypoglycemic Drug Sales by Type (2021-2026) & (K Units)
Table 24. Global Non-Insulin Hypoglycemic Drug Sales by Type (2027-2032) & (K Units)
Table 25. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Type (2021-2026)
Table 26. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Type (2027-2032)
Table 27. Global Non-Insulin Hypoglycemic Drug Revenue by Type 2021 VS 2025 VS 2032 (K Units)
Table 28. Global Non-Insulin Hypoglycemic Drug Revenue by Type (2021-2026) & (K Units)
Table 29. Global Non-Insulin Hypoglycemic Drug Revenue by Type (2027-2032) & (K Units)
Table 30. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Type (2021-2026)
Table 31. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Type (2027-2032)
Table 32. Major Manufacturers of Hospital Pharmacies
Table 33. Major Manufacturers of Retail Pharmacies
Table 34. Global Non-Insulin Hypoglycemic Drug Sales by Application 2021 VS 2025 VS 2032 (K Units)
Table 35. Global Non-Insulin Hypoglycemic Drug Sales by Application (2021-2026) & (K Units)
Table 36. Global Non-Insulin Hypoglycemic Drug Sales by Application (2027-2032) & (K Units)
Table 37. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Application (2021-2026)
Table 38. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Application (2027-2032)
Table 39. Global Non-Insulin Hypoglycemic Drug Revenue by Application 2021 VS 2025 VS 2032 (K Units)
Table 40. Global Non-Insulin Hypoglycemic Drug Revenue by Application (2021-2026) & (K Units)
Table 41. Global Non-Insulin Hypoglycemic Drug Revenue by Application (2027-2032) & (K Units)
Table 42. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Application (2021-2026)
Table 43. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Application (2027-2032)
Table 44. Global Non-Insulin Hypoglycemic Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units)
Table 45. Global Non-Insulin Hypoglycemic Drug Sales by Region (2021-2026) & (K Units)
Table 46. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Region (2021-2026)
Table 47. Global Non-Insulin Hypoglycemic Drug Sales Forecasted by Region (2027-2032) & (K Units)
Table 48. Global Non-Insulin Hypoglycemic Drug Sales Forecasted Market Share by Region (2027-2032)
Table 49. North America Non-Insulin Hypoglycemic Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units)
Table 50. North America Non-Insulin Hypoglycemic Drug Sales by Country (2021-2026) & (K Units)
Table 51. North America Non-Insulin Hypoglycemic Drug Sales by Country (2027-2032) & (K Units)
Table 52. Europe Non-Insulin Hypoglycemic Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units)
Table 53. Europe Non-Insulin Hypoglycemic Drug Sales by Country (2021-2026) & (K Units)
Table 54. Europe Non-Insulin Hypoglycemic Drug Sales by Country (2027-2032) & (K Units)
Table 55. Asia Pacific Non-Insulin Hypoglycemic Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units)
Table 56. Asia Pacific Non-Insulin Hypoglycemic Drug Sales by Country (2021-2026) & (K Units)
Table 57. Asia Pacific Non-Insulin Hypoglycemic Drug Sales by Country (2027-2032) & (K Units)
Table 58. South America, Middle East and Africa Non-Insulin Hypoglycemic Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units)
Table 59. South America, Middle East and Africa Non-Insulin Hypoglycemic Drug Sales by Country (2021-2026) & (K Units)
Table 60. South America, Middle East and Africa Non-Insulin Hypoglycemic Drug Sales by Country (2027-2032) & (K Units)
Table 61. Global Non-Insulin Hypoglycemic Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million)
Table 62. Global Non-Insulin Hypoglycemic Drug Revenue by Region (2021-2026) & (US$ Million)
Table 63. Global Non-Insulin Hypoglycemic Drug Revenue by Region (2027-2032) & (US$ Million)
Table 64. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Region (2021-2026)
Table 65. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Region (2027-2032)
Table 66. GSK Company Information
Table 67. GSK Business Overview
Table 68. GSK Non-Insulin Hypoglycemic Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 69. GSK Non-Insulin Hypoglycemic Drug Product Portfolio
Table 70. GSK Recent Development
Table 71. Takeda Company Information
Table 72. Takeda Business Overview
Table 73. Takeda Non-Insulin Hypoglycemic Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 74. Takeda Non-Insulin Hypoglycemic Drug Product Portfolio
Table 75. Takeda Recent Development
Table 76. Merck Company Information
Table 77. Merck Business Overview
Table 78. Merck Non-Insulin Hypoglycemic Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 79. Merck Non-Insulin Hypoglycemic Drug Product Portfolio
Table 80. Merck Recent Development
Table 81. Uni-Bio Science Group Company Information
Table 82. Uni-Bio Science Group Business Overview
Table 83. Uni-Bio Science Group Non-Insulin Hypoglycemic Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 84. Uni-Bio Science Group Non-Insulin Hypoglycemic Drug Product Portfolio
Table 85. Uni-Bio Science Group Recent Development
Table 86. Eli Lilly Company Information
Table 87. Eli Lilly Business Overview
Table 88. Eli Lilly Non-Insulin Hypoglycemic Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. Eli Lilly Non-Insulin Hypoglycemic Drug Product Portfolio
Table 90. Eli Lilly Recent Development
Table 91. Jiangsu Hengrui Medicine Company Information
Table 92. Jiangsu Hengrui Medicine Business Overview
Table 93. Jiangsu Hengrui Medicine Non-Insulin Hypoglycemic Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. Jiangsu Hengrui Medicine Non-Insulin Hypoglycemic Drug Product Portfolio
Table 95. Jiangsu Hengrui Medicine Recent Development
Table 96. Jiangsu Hansoh Pharmaceutical Company Information
Table 97. Jiangsu Hansoh Pharmaceutical Business Overview
Table 98. Jiangsu Hansoh Pharmaceutical Non-Insulin Hypoglycemic Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 99. Jiangsu Hansoh Pharmaceutical Non-Insulin Hypoglycemic Drug Product Portfolio
Table 100. Jiangsu Hansoh Pharmaceutical Recent Development
Table 101. Pfizer Company Information
Table 102. Pfizer Business Overview
Table 103. Pfizer Non-Insulin Hypoglycemic Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 104. Pfizer Non-Insulin Hypoglycemic Drug Product Portfolio
Table 105. Pfizer Recent Development
Table 106. Sumitomo Dainippon Pharma Company Information
Table 107. Sumitomo Dainippon Pharma Business Overview
Table 108. Sumitomo Dainippon Pharma Non-Insulin Hypoglycemic Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 109. Sumitomo Dainippon Pharma Non-Insulin Hypoglycemic Drug Product Portfolio
Table 110. Sumitomo Dainippon Pharma Recent Development
Table 111. Servier Company Information
Table 112. Servier Business Overview
Table 113. Servier Non-Insulin Hypoglycemic Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 114. Servier Non-Insulin Hypoglycemic Drug Product Portfolio
Table 115. Servier Recent Development
Table 116. Novo Nordisk Company Information
Table 117. Novo Nordisk Business Overview
Table 118. Novo Nordisk Non-Insulin Hypoglycemic Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 119. Novo Nordisk Non-Insulin Hypoglycemic Drug Product Portfolio
Table 120. Novo Nordisk Recent Development
Table 121. Luye Pharma Group Company Information
Table 122. Luye Pharma Group Business Overview
Table 123. Luye Pharma Group Non-Insulin Hypoglycemic Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 124. Luye Pharma Group Non-Insulin Hypoglycemic Drug Product Portfolio
Table 125. Luye Pharma Group Recent Development
Table 126. Intarcia Therapeutics Company Information
Table 127. Intarcia Therapeutics Business Overview
Table 128. Intarcia Therapeutics Non-Insulin Hypoglycemic Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 129. Intarcia Therapeutics Non-Insulin Hypoglycemic Drug Product Portfolio
Table 130. Intarcia Therapeutics Recent Development
Table 131. Geropharm Company Information
Table 132. Geropharm Business Overview
Table 133. Geropharm Non-Insulin Hypoglycemic Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 134. Geropharm Non-Insulin Hypoglycemic Drug Product Portfolio
Table 135. Geropharm Recent Development
Table 136. Eurofarma Company Information
Table 137. Eurofarma Business Overview
Table 138. Eurofarma Non-Insulin Hypoglycemic Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 139. Eurofarma Non-Insulin Hypoglycemic Drug Product Portfolio
Table 140. Eurofarma Recent Development
Table 141. Emisphere Company Information
Table 142. Emisphere Business Overview
Table 143. Emisphere Non-Insulin Hypoglycemic Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 144. Emisphere Non-Insulin Hypoglycemic Drug Product Portfolio
Table 145. Emisphere Recent Development
Table 146. Dong-A Pharmaceutical Company Information
Table 147. Dong-A Pharmaceutical Business Overview
Table 148. Dong-A Pharmaceutical Non-Insulin Hypoglycemic Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 149. Dong-A Pharmaceutical Non-Insulin Hypoglycemic Drug Product Portfolio
Table 150. Dong-A Pharmaceutical Recent Development
Table 151. Alkem Labs Company Information
Table 152. Alkem Labs Business Overview
Table 153. Alkem Labs Non-Insulin Hypoglycemic Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 154. Alkem Labs Non-Insulin Hypoglycemic Drug Product Portfolio
Table 155. Alkem Labs Recent Development
Table 156. 3SBio Company Information
Table 157. 3SBio Business Overview
Table 158. 3SBio Non-Insulin Hypoglycemic Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 159. 3SBio Non-Insulin Hypoglycemic Drug Product Portfolio
Table 160. 3SBio Recent Development
Table 161. Key Raw Materials
Table 162. Raw Materials Key Suppliers
Table 163. Non-Insulin Hypoglycemic Drug Distributors List
Table 164. Non-Insulin Hypoglycemic Drug Customers List
Table 165. Research Programs/Design for This Report
Table 166. Authors List of This Report
Table 167. Secondary Sources
Table 168. Primary Sources
List of Figures
Figure 1. Non-Insulin Hypoglycemic Drug Product Image
Figure 2. Global Non-Insulin Hypoglycemic Drug Market Size (US$ Million), 2021 VS 2025 VS 2032
Figure 3. Global Non-Insulin Hypoglycemic Drug Market Size (2021-2032) & (US$ Million)
Figure 4. Global Non-Insulin Hypoglycemic Drug Sales (2021-2032) & (K Units)
Figure 5. Global Non-Insulin Hypoglycemic Drug Average Price (US$/Unit) & (2021-2032)
Figure 6. Global Top 5 and 10 Non-Insulin Hypoglycemic Drug Players Market Share by Revenue in 2025
Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 8. Alpha Glucosidase Inhibitors Image
Figure 9. Meglitinides Image
Figure 10. Sulfonylureas Image
Figure 11. Thiazolidinediones Image
Figure 12. Biguanides Image
Figure 13. Others Image
Figure 14. Global Non-Insulin Hypoglycemic Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units)
Figure 15. Global Non-Insulin Hypoglycemic Drug Sales Market Share 2021 VS 2025 VS 2032
Figure 16. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Type (2021-2032)
Figure 17. Global Non-Insulin Hypoglycemic Drug Revenue by Type (2021 VS 2025 VS 2032) & (K Units)
Figure 18. Global Non-Insulin Hypoglycemic Drug Revenue Market Share 2021 VS 2025 VS 2032
Figure 19. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Type (2021-2032)
Figure 20. Hospital Pharmacies Image
Figure 21. Retail Pharmacies Image
Figure 22. Global Non-Insulin Hypoglycemic Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units)
Figure 23. Global Non-Insulin Hypoglycemic Drug Sales Market Share 2021 VS 2025 VS 2032
Figure 24. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Application (2021-2032)
Figure 25. Global Non-Insulin Hypoglycemic Drug Revenue by Application (2021 VS 2025 VS 2032) & (K Units)
Figure 26. Global Non-Insulin Hypoglycemic Drug Revenue Market Share 2021 VS 2025 VS 2032
Figure 27. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Application (2021-2032)
Figure 28. North America Non-Insulin Hypoglycemic Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 29. North America Non-Insulin Hypoglycemic Drug Sales Market Share by Country (2021-2032)
Figure 30. U.S. Non-Insulin Hypoglycemic Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 31. Canada Non-Insulin Hypoglycemic Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 32. Mexico Non-Insulin Hypoglycemic Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 33. Europe Non-Insulin Hypoglycemic Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 34. Europe Non-Insulin Hypoglycemic Drug Sales Market Share by Country (2021-2032)
Figure 35. Germany Non-Insulin Hypoglycemic Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 36. France Non-Insulin Hypoglycemic Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 37. U.K. Non-Insulin Hypoglycemic Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 38. Italy Non-Insulin Hypoglycemic Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 39. Netherlands Non-Insulin Hypoglycemic Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 40. Asia Pacific Non-Insulin Hypoglycemic Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 41. Asia Pacific Non-Insulin Hypoglycemic Drug Sales Market Share by Country (2021-2032)
Figure 42. China Non-Insulin Hypoglycemic Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 43. Japan Non-Insulin Hypoglycemic Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 44. South Korea Non-Insulin Hypoglycemic Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 45. Southeast Asia Non-Insulin Hypoglycemic Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 46. India Non-Insulin Hypoglycemic Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 47. Australia Non-Insulin Hypoglycemic Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 48. South America, Middle East and Africa Non-Insulin Hypoglycemic Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 49. South America, Middle East and Africa Non-Insulin Hypoglycemic Drug Sales Market Share by Country (2021-2032)
Figure 50. Brazil Non-Insulin Hypoglycemic Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 51. South Africa Non-Insulin Hypoglycemic Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 52. Saudi Arabia Non-Insulin Hypoglycemic Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 53. Turkey Non-Insulin Hypoglycemic Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 54. Argentina Non-Insulin Hypoglycemic Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 55. UAE Non-Insulin Hypoglycemic Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 56. Egypt Non-Insulin Hypoglycemic Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 57. Chile Non-Insulin Hypoglycemic Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 58. Global Non-Insulin Hypoglycemic Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million)
Figure 59. Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032
Figure 60. North America Non-Insulin Hypoglycemic Drug Revenue (2021-2032) & (US$ Million)
Figure 61. North America Non-Insulin Hypoglycemic Drug Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 62. Europe Non-Insulin Hypoglycemic Drug Revenue (2021-2032) & (US$ Million)
Figure 63. Europe Non-Insulin Hypoglycemic Drug Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 64. Asia-Pacific Non-Insulin Hypoglycemic Drug Revenue (2021-2032) & (US$ Million)
Figure 65. Asia-Pacific Non-Insulin Hypoglycemic Drug Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 66. South America, Middle East and Africa Non-Insulin Hypoglycemic Drug Revenue (2021-2032) & (US$ Million)
Figure 67. South America, Middle East and Africa Non-Insulin Hypoglycemic Drug Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 68. Non-Insulin Hypoglycemic Drug Value Chain
Figure 69. Manufacturing Cost Structure
Figure 70. Non-Insulin Hypoglycemic Drug Production Mode & Process
Figure 71. Direct Comparison with Distribution Share
Figure 72. Distributors Profiles
Figure 73. Years Considered
Figure 74. Research Process
Figure 75. Key Executives Interviewed
Scope & coverage.
Types
- Alpha Glucosidase Inhibitors
- Meglitinides
- Sulfonylureas
- Thiazolidinediones
- Biguanides
- Others
Applications
- Hospital Pharmacies
- Retail Pharmacies
Companies covered
- GSK
- Takeda
- Merck
- Uni-Bio Science Group
- Eli Lilly
- Jiangsu Hengrui Medicine
- Jiangsu Hansoh Pharmaceutical
- Pfizer
- Sumitomo Dainippon Pharma
- Servier
- Novo Nordisk
- Luye Pharma Group
- Intarcia Therapeutics
- Geropharm
- Eurofarma
- Emisphere
- Dong-A Pharmaceutical
- Alkem Labs
- 3SBio
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Non-Insulin Hypoglycemic Drug Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Non-Insulin Hypoglycemic Drug Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Non-Insulin Hypoglycemic Drug Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Non-Insulin Hypoglycemic Drug Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Non-Insulin Hypoglycemic Drug Market Dynamics
- 2.1 Non-Insulin Hypoglycemic Drug Industry Trends
- 2.2 Non-Insulin Hypoglycemic Drug Industry Drivers
- 2.3 Non-Insulin Hypoglycemic Drug Industry Opportunities and Challenges
- 2.4 Non-Insulin Hypoglycemic Drug Industry Restraints
3 Non-Insulin Hypoglycemic Drug Market by Manufacturers
- 3.1 Global Non-Insulin Hypoglycemic Drug Revenue by Manufacturers (2021-2026)
- 3.2 Global Non-Insulin Hypoglycemic Drug Sales by Manufacturers (2021-2026)
- 3.3 Global Non-Insulin Hypoglycemic Drug Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Non-Insulin Hypoglycemic Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Non-Insulin Hypoglycemic Drug Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Non-Insulin Hypoglycemic Drug Manufacturers, Product Type & Application
- 3.7 Global Non-Insulin Hypoglycemic Drug Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Non-Insulin Hypoglycemic Drug Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Non-Insulin Hypoglycemic Drug Players Market Share by Revenue in 2025
- 3.8.3 2025 Non-Insulin Hypoglycemic Drug Tier 1, Tier 2, and Tier 3
4 Non-Insulin Hypoglycemic Drug Market by Type
- 4.1 Non-Insulin Hypoglycemic Drug Type Introduction
- 4.1.1 Alpha Glucosidase Inhibitors
- 4.1.2 Meglitinides
- 4.1.3 Sulfonylureas
- 4.1.4 Thiazolidinediones
- 4.1.5 Biguanides
- 4.1.6 Others
- 4.2 Global Non-Insulin Hypoglycemic Drug Sales by Type
- 4.2.1 Global Non-Insulin Hypoglycemic Drug Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Non-Insulin Hypoglycemic Drug Sales by Type (2021-2032)
- 4.2.3 Global Non-Insulin Hypoglycemic Drug Sales Market Share by Type (2021-2032)
- 4.3 Global Non-Insulin Hypoglycemic Drug Revenue by Type
- 4.3.1 Global Non-Insulin Hypoglycemic Drug Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Non-Insulin Hypoglycemic Drug Revenue by Type (2021-2032)
- 4.3.3 Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Type (2021-2032)
5 Non-Insulin Hypoglycemic Drug Market by Application
- 5.1 Non-Insulin Hypoglycemic Drug Application Introduction
- 5.1.1 Hospital Pharmacies
- 5.1.2 Retail Pharmacies
- 5.2 Global Non-Insulin Hypoglycemic Drug Sales by Application
- 5.2.1 Global Non-Insulin Hypoglycemic Drug Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Non-Insulin Hypoglycemic Drug Sales by Application (2021-2032)
- 5.2.3 Global Non-Insulin Hypoglycemic Drug Sales Market Share by Application (2021-2032)
- 5.3 Global Non-Insulin Hypoglycemic Drug Revenue by Application
- 5.3.1 Global Non-Insulin Hypoglycemic Drug Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Non-Insulin Hypoglycemic Drug Revenue by Application (2021-2032)
- 5.3.3 Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Application (2021-2032)
6 Global Non-Insulin Hypoglycemic Drug Sales by Region
- 6.1 Global Non-Insulin Hypoglycemic Drug Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Non-Insulin Hypoglycemic Drug Sales by Region (2021-2032)
- 6.2.1 Global Non-Insulin Hypoglycemic Drug Sales by Region (2021-2026)
- 6.2.2 Global Non-Insulin Hypoglycemic Drug Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Non-Insulin Hypoglycemic Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Non-Insulin Hypoglycemic Drug Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Non-Insulin Hypoglycemic Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Non-Insulin Hypoglycemic Drug Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Non-Insulin Hypoglycemic Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Non-Insulin Hypoglycemic Drug Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Non-Insulin Hypoglycemic Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Non-Insulin Hypoglycemic Drug Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Non-Insulin Hypoglycemic Drug Revenue by Region
- 7.1 Global Non-Insulin Hypoglycemic Drug Revenue by Region
- 7.1.1 Global Non-Insulin Hypoglycemic Drug Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Non-Insulin Hypoglycemic Drug Revenue by Region (2021-2026)
- 7.1.3 Global Non-Insulin Hypoglycemic Drug Revenue by Region (2027-2032)
- 7.1.4 Global Non-Insulin Hypoglycemic Drug Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Non-Insulin Hypoglycemic Drug Revenue (2021-2032)
- 7.2.2 North America Non-Insulin Hypoglycemic Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Non-Insulin Hypoglycemic Drug Revenue (2021-2032)
- 7.3.2 Europe Non-Insulin Hypoglycemic Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Non-Insulin Hypoglycemic Drug Revenue (2021-2032)
- 7.4.2 Asia-Pacific Non-Insulin Hypoglycemic Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Non-Insulin Hypoglycemic Drug Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Non-Insulin Hypoglycemic Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 GSK
- 8.1.1 GSK Company Information
- 8.1.2 GSK Business Overview
- 8.1.3 GSK Non-Insulin Hypoglycemic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 GSK Non-Insulin Hypoglycemic Drug Product Portfolio
- 8.1.5 GSK Recent Developments
- 8.2 Takeda
- 8.2.1 Takeda Company Information
- 8.2.2 Takeda Business Overview
- 8.2.3 Takeda Non-Insulin Hypoglycemic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Takeda Non-Insulin Hypoglycemic Drug Product Portfolio
- 8.2.5 Takeda Recent Developments
- 8.3 Merck
- 8.3.1 Merck Company Information
- 8.3.2 Merck Business Overview
- 8.3.3 Merck Non-Insulin Hypoglycemic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Merck Non-Insulin Hypoglycemic Drug Product Portfolio
- 8.3.5 Merck Recent Developments
- 8.4 Uni-Bio Science Group
- 8.4.1 Uni-Bio Science Group Company Information
- 8.4.2 Uni-Bio Science Group Business Overview
- 8.4.3 Uni-Bio Science Group Non-Insulin Hypoglycemic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Uni-Bio Science Group Non-Insulin Hypoglycemic Drug Product Portfolio
- 8.4.5 Uni-Bio Science Group Recent Developments
- 8.5 Eli Lilly
- 8.5.1 Eli Lilly Company Information
- 8.5.2 Eli Lilly Business Overview
- 8.5.3 Eli Lilly Non-Insulin Hypoglycemic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Eli Lilly Non-Insulin Hypoglycemic Drug Product Portfolio
- 8.5.5 Eli Lilly Recent Developments
- 8.6 Jiangsu Hengrui Medicine
- 8.6.1 Jiangsu Hengrui Medicine Company Information
- 8.6.2 Jiangsu Hengrui Medicine Business Overview
- 8.6.3 Jiangsu Hengrui Medicine Non-Insulin Hypoglycemic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Jiangsu Hengrui Medicine Non-Insulin Hypoglycemic Drug Product Portfolio
- 8.6.5 Jiangsu Hengrui Medicine Recent Developments
- 8.7 Jiangsu Hansoh Pharmaceutical
- 8.7.1 Jiangsu Hansoh Pharmaceutical Company Information
- 8.7.2 Jiangsu Hansoh Pharmaceutical Business Overview
- 8.7.3 Jiangsu Hansoh Pharmaceutical Non-Insulin Hypoglycemic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Jiangsu Hansoh Pharmaceutical Non-Insulin Hypoglycemic Drug Product Portfolio
- 8.7.5 Jiangsu Hansoh Pharmaceutical Recent Developments
- 8.8 Pfizer
- 8.8.1 Pfizer Company Information
- 8.8.2 Pfizer Business Overview
- 8.8.3 Pfizer Non-Insulin Hypoglycemic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Pfizer Non-Insulin Hypoglycemic Drug Product Portfolio
- 8.8.5 Pfizer Recent Developments
- 8.9 Sumitomo Dainippon Pharma
- 8.9.1 Sumitomo Dainippon Pharma Company Information
- 8.9.2 Sumitomo Dainippon Pharma Business Overview
- 8.9.3 Sumitomo Dainippon Pharma Non-Insulin Hypoglycemic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Sumitomo Dainippon Pharma Non-Insulin Hypoglycemic Drug Product Portfolio
- 8.9.5 Sumitomo Dainippon Pharma Recent Developments
- 8.10 Servier
- 8.10.1 Servier Company Information
- 8.10.2 Servier Business Overview
- 8.10.3 Servier Non-Insulin Hypoglycemic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Servier Non-Insulin Hypoglycemic Drug Product Portfolio
- 8.10.5 Servier Recent Developments
- 8.11 Novo Nordisk
- 8.11.1 Novo Nordisk Company Information
- 8.11.2 Novo Nordisk Business Overview
- 8.11.3 Novo Nordisk Non-Insulin Hypoglycemic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Novo Nordisk Non-Insulin Hypoglycemic Drug Product Portfolio
- 8.11.5 Novo Nordisk Recent Developments
- 8.12 Luye Pharma Group
- 8.12.1 Luye Pharma Group Company Information
- 8.12.2 Luye Pharma Group Business Overview
- 8.12.3 Luye Pharma Group Non-Insulin Hypoglycemic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 Luye Pharma Group Non-Insulin Hypoglycemic Drug Product Portfolio
- 8.12.5 Luye Pharma Group Recent Developments
- 8.13 Intarcia Therapeutics
- 8.13.1 Intarcia Therapeutics Company Information
- 8.13.2 Intarcia Therapeutics Business Overview
- 8.13.3 Intarcia Therapeutics Non-Insulin Hypoglycemic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.13.4 Intarcia Therapeutics Non-Insulin Hypoglycemic Drug Product Portfolio
- 8.13.5 Intarcia Therapeutics Recent Developments
- 8.14 Geropharm
- 8.14.1 Geropharm Company Information
- 8.14.2 Geropharm Business Overview
- 8.14.3 Geropharm Non-Insulin Hypoglycemic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.14.4 Geropharm Non-Insulin Hypoglycemic Drug Product Portfolio
- 8.14.5 Geropharm Recent Developments
- 8.15 Eurofarma
- 8.15.1 Eurofarma Company Information
- 8.15.2 Eurofarma Business Overview
- 8.15.3 Eurofarma Non-Insulin Hypoglycemic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.15.4 Eurofarma Non-Insulin Hypoglycemic Drug Product Portfolio
- 8.15.5 Eurofarma Recent Developments
- 8.16 Emisphere
- 8.16.1 Emisphere Company Information
- 8.16.2 Emisphere Business Overview
- 8.16.3 Emisphere Non-Insulin Hypoglycemic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.16.4 Emisphere Non-Insulin Hypoglycemic Drug Product Portfolio
- 8.16.5 Emisphere Recent Developments
- 8.17 Dong-A Pharmaceutical
- 8.17.1 Dong-A Pharmaceutical Company Information
- 8.17.2 Dong-A Pharmaceutical Business Overview
- 8.17.3 Dong-A Pharmaceutical Non-Insulin Hypoglycemic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.17.4 Dong-A Pharmaceutical Non-Insulin Hypoglycemic Drug Product Portfolio
- 8.17.5 Dong-A Pharmaceutical Recent Developments
- 8.18 Alkem Labs
- 8.18.1 Alkem Labs Company Information
- 8.18.2 Alkem Labs Business Overview
- 8.18.3 Alkem Labs Non-Insulin Hypoglycemic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.18.4 Alkem Labs Non-Insulin Hypoglycemic Drug Product Portfolio
- 8.18.5 Alkem Labs Recent Developments
- 8.19 3SBio
- 8.19.1 3SBio Company Information
- 8.19.2 3SBio Business Overview
- 8.19.3 3SBio Non-Insulin Hypoglycemic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.19.4 3SBio Non-Insulin Hypoglycemic Drug Product Portfolio
- 8.19.5 3SBio Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Non-Insulin Hypoglycemic Drug Value Chain Analysis
- 9.1.1 Non-Insulin Hypoglycemic Drug Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Non-Insulin Hypoglycemic Drug Production Mode & Process
- 9.2 Non-Insulin Hypoglycemic Drug Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Non-Insulin Hypoglycemic Drug Distributors
- 9.2.3 Non-Insulin Hypoglycemic Drug Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$3,950USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst